Table 2.
Efficacy of Generic Oral DAA Regimens for Chronic HCV Infection in Real-world Cohorts
| Author/year | Country | Regimen | Population | N | SVR 12 |
|---|---|---|---|---|---|
| Premkumar (2017) | India | sofosbuvir/daclatasvir/ribavirin | GT1-4 | 11,105 | 93% |
| Goel (2017) | India | sofosbuvir/daclatasvir +/− ribavirin | GT3 | 100 | 91.9% |
| Zeng (2017) | China | sofosbuvir/ledipasvir +/− ribavirin | GT1b | 192 | 96.9% |
| Freeman (2016) | International | sofosbuvir/ledipasvir or sofosbuvir/daclatasvir | GT1-6 | 448 | 90-100% |
| Hajarizadeh (2017) | Iran | sofosbuvir/daclatasvir | GT1 and 3 Cirrhosis or Post-Transplant | 104 | 98% |
| Yakoot (2016) | Egypt | sofosbuvir/ribavirin | GT4 | 48 | 95.8% |
| Sharma (2018) | India | sofosbuvir/ledipasvir or sofosbuvir/daclatasvir | GT1 and 3 CKD | 71 | 100% |
| Liu (2018) | Taiwan | Sofosbuvir/velpatasvir | HCV and HCV/HIV | 228 | 97.1-98.1% |
| Gupta (2018) | India | sofosbuvir/ribavirin,ledipasvir, daclatasvir | GT1 and 3 | 499 | 95.9% |
| Omar (2018) | Egypt | sofosbuvir/daclatasvir +/− ribavirin | GT4 | 18,378 | 95.1% |
| Hill (2017) | International | sofosbuvir/ledipasvir or sofosbuvir/daclatasvir | GT1-6 | 616 | 99% |
| Nagral (2017) | India | sofosbuvir/ledipasvir or sofosbuvir/daclatasvir | GT1 and 3 Thalassemia | 29 | 100% |
| Marciano (2018) | Argentina | sofosbuvir/daclatasvir; sofosbuvir/daclatasvir/ribavirin; or sofosbuvir/ribavirin | GT1 | 321 | 90% |